Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 3 drugs
Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use...
Approved
Investigational
Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors than clonidine or...
Approved
Matched Description: … Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors than [clonidine] or ... [A178945] Thus brimonidine is an effective and safe alternative to beta-blockers, in patients with, or
Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide...
Approved
Matched Description: … A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or ... [A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances …
Displaying all 3 drugs